Drug Overview

Ravulizumab is a breakthrough biological medication designed to manage rare and serious diseases where the body’s immune system accidentally attacks its own healthy cells. It is recognized as a Targeted Therapy because it focuses on a very specific part of the immune system called the “complement system.” By acting as a high-precision shield, it prevents the destruction of red blood cells and damage to vital organs like the kidneys.

In the medical community, Ravulizumab is known as a “long-acting” inhibitor. This means it stays in the body much longer than older treatments, allowing patients to receive therapy less often—sometimes only once every eight weeks. This “Smart Drug” approach offers a corporate standard of care that prioritizes both clinical results and the patient’s quality of life.

Generic Name: Ravulizumab-cwvz
US Brand Names: Ultomiris
Drug Class: Complement Inhibitor; Monoclonal Antibody
Route of Administration: Intravenous (IV) Infusion or Subcutaneous (SC) Injection
FDA Approval Status: FDA Approved

What Is It and How Does It Work? (Mechanism of Action)

To understand how Ravulizumab works, imagine your immune system has a “demolition crew” called the Complement System. Its job is to destroy invading bacteria. However, in certain diseases, this crew gets confused and starts attacking the body’s own “buildings” (cells). Ravulizumab acts as the supervisor who steps in and shuts down the demolition equipment.

At the molecular level, the drug operates through a precise biological blockade:

Targeting the C5 Protein: Ravulizumab is a humanized monoclonal antibody that binds specifically to the complement protein C5.
Blocking Cleavage: Normally, the body breaks down C5 into two smaller pieces, C5a and C5b. Ravulizumab attaches to C5 and prevents this break from happening.
Stopping the Membrane Attack Complex (MAC): Without the C5b piece, the body cannot form the “Membrane Attack Complex.” This complex is like a biological drill that punches holes in cell membranes.
Cell Protection: By stopping the MAC from forming, Ravulizumab prevents the “lysis” (bursting) of red blood cells and prevents inflammation in the blood vessels.
Recycling Technology: A unique feature of Ravulizumab is its “recycling” ability. After it does its job, the drug is released back into the bloodstream to be used again, which is why it lasts so much longer than previous generations of medicine.

FDA-Approved Clinical Indications

Ravulizumab is used to treat several life-threatening conditions. While it is not a direct “cancer killer,” it is used in oncology-related settings where blood cells are being destroyed.

Oncological and Hematological Uses

Paroxysmal Nocturnal Hemoglobinuria (PNH): A rare blood disease where the immune system destroys red blood cells.
Atypical Hemolytic Uremic Syndrome (aHUS): A condition that causes abnormal blood clots in small blood vessels, often leading to kidney failure.

Non-Oncological Uses

Generalized Myasthenia Gravis (gMG): A chronic autoimmune disease that causes muscle weakness.
Neuromyelitis Optica Spectrum Disorder (NMOSD): An autoimmune disease of the central nervous system that affects the optic nerves and spinal cord.

Dosage and Administration Protocols

Ravulizumab is administered based on the patient’s body weight. The treatment starts with a “loading dose” followed by “maintenance doses.”

Patient Weight Range	Loading Dose	Maintenance Dose (Every 8 Weeks)	Infusion Time
40 kg to <60 kg	2,400 mg	3,000 mg	45–60 minutes
60 kg to <100 kg	2,700 mg	3,300 mg	45–60 minutes
100 kg or greater	3,000 mg	3,600 mg	45–140 minutes

Dose Adjustments:

Renal/Hepatic Insufficiency: No specific dose adjustments are required for patients with kidney or liver impairment, as monoclonal antibodies are not primarily cleared by these organs.

Clinical Efficacy and Research Results

Clinical data from 2020–2025 confirms that Ravulizumab is highly effective at stopping cell destruction.

PNH Results: In Phase III trials, over 73% of patients who switched from older medications (like Eculizumab) to Ravulizumab maintained stable hemoglobin levels without needing blood transfusions.
Kidney Health (aHUS): Numerical data shows that over 50% of adult patients achieved a “Complete Thrombotic Microangiopathy (TMA) Response,” meaning their blood counts returned to normal and their kidney function significantly improved.
Survival Rates: Long-term follow-up studies (2024) indicate that with consistent use, the survival rate of patients with PNH is now nearly identical to that of the general population.

Safety Profile and Side Effects

Black Box Warning:

WARNING: SERIOUS MENINGOCOCCAL INFECTIONS. Ravulizumab increases the risk of life-threatening meningitis. Patients must be vaccinated against meningococcal bacteria at least two weeks before starting treatment.

Common Side Effects (>10%)

Upper Respiratory Tract Infection: Such as the common cold or sore throat.
Headache: Often mild and manageable with standard over-the-counter medicine.
Diarrhea or Nausea: General stomach upset following infusion.
Hypertension: A temporary increase in blood pressure.

Serious Adverse Events

Septicemia: Severe blood infections.
Infusion-Related Reactions: Allergic reactions during the IV drip.
Autoimmune Reactions: Rare instances where the body reacts to the medication itself.

Management Strategies

Vaccination Tracking: All patients must carry a “Patient Safety Card” at all times to show they are taking this medication.
Antibiotic Prophylaxis: If treatment must start before the vaccine is effective, doctors will prescribe a two-week course of antibiotics.

Research Areas

In the fields of Regenerative Medicine and Immunotherapy, researchers are investigating if Ravulizumab can help protect Stem Cell Transplants. Sometimes, the “demolition crew” of the complement system attacks newly transplanted stem cells (a condition called TMA). Current research is exploring if Ravulizumab can act as a shield to help these new cells “take” and regenerate healthy blood. There is also interest in using this drug to prevent inflammation after organ transplants.

Patient Management and Practical Recommendations

Pre-treatment Tests to be Performed

Meningococcal Vaccine Status: Confirmation of vaccination (Serogroups A, C, W, Y, and B).
Baseline Blood Counts (CBC): To check current red cell and platelet levels.
Kidney Function Tests (Creatinine).

Precautions During Treatment

Fever Watch: Report any fever over 100.4°F (38°C) immediately; this could be a sign of a serious infection.
Consistent Schedule: Because the drug is long-acting, missing a dose by even a few days can cause the disease to “rebound” and destroy blood cells rapidly.

“Do’s and Don’ts” List

Do carry your Patient Safety Card in your wallet at all times.
Do keep every scheduled appointment for your 8-week infusion.
Don’t ignore a stiff neck, headache with nausea, or light sensitivity; these are signs of meningitis.
Don’t stop treatment without a detailed plan from your hematologist.

Legal Disclaimer

Standard medical information disclaimer: This guide is for informational purposes only and does not constitute medical advice. Ravulizumab is a high-potency prescription medication. Always consult with a licensed hematologist or oncologist to discuss your specific diagnosis and treatment plan. This content reflects clinical data available as of 2026.